DGAVP
Also known as: Desglycinamide-arginine-vasopressin · des-Gly-9-[8-arginine]-vasopressin
A classical De Wied-laboratory vasopressin analogue engineered to preserve memory-relevant central effects while eliminating the pressor effect of parent vasopressin — the reference vasopressin-family cognitive research peptide of the 1970s-80s.
DGAVP is a classical De Wied-laboratory vasopressin analogue engineered to preserve memory-relevant central effects while eliminating pressor effect; historically significant, contemporary research use limited.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Cognitive Enhancement
- Half-life
- Short plasma half-life; central pharmacodynamic effects extend beyond exposure
Section 1
Overview
DGAVP (desglycinamide-arginine-vasopressin) is a modified analogue of arginine vasopressin engineered in the De Wied laboratory at the Rudolf Magnus Institute of Utrecht as part of the systematic effort to separate vasopressin's central memory-related effects from its peripheral pressor and antidiuretic effects. The C-terminal glycinamide is removed, producing an analogue that retains the memory-relevant central pharmacology while losing much of the peripheral cardiovascular activity.
The compound is included on this reference for historical significance. The De Wied laboratory work on vasopressin-family cognitive effects, running from the 1960s through the 1990s, established the foundational concept that peptide-family molecules could be engineered as memory-modulating research tools — a concept that subsequently informed the Russian Semax and Selank programmes and, through them, the modern cognitive-peptide research field.
Direct current research use of DGAVP is limited. The molecule remains available as a research chemical for classical vasopressin-family research applications, but it is not a mainstream contemporary cognitive-peptide research tool. Its inclusion here provides the historical context for the vasopressin-family cognitive research programme and completes the vasopressin-family coverage on this reference.
Section 2
Discovery & History
- Synthesised in the De Wied laboratory at the Rudolf Magnus Institute of the University of Utrecht in the 1970s as part of the systematic vasopressin-analogue engineering programme.
- Extensively characterised in animal and human research through the 1970s and 1980s, establishing the phenotypic separation of central memory effects from peripheral pressor effects.
- Reported memory-modulation effects in age-related-cognitive-decline populations, alcohol amnestic states, and other memory-impairment research contexts, though effect sizes were modest and replication was inconsistent.
- The compound never entered clinical development towards marketing authorisation; the De Wied laboratory programme was academic research rather than pharmaceutical development.
- Remains a research chemical in all jurisdictions, primarily used in specialised vasopressin-family research applications.
Section 3
Mechanism of Action
- 1Selective central V1a and V1b receptor engagement with markedly reduced peripheral V2 receptor activity — the pharmacological separation that motivated the analogue's design and the property that distinguishes DGAVP from parent vasopressin.
- 2Central memory-relevant neurocircuitry engagement — reported effects on hippocampal and amygdalar function relevant to memory consolidation and retrieval via V1a receptor activation on cognate CNS neuronal populations.
- 3Reduced pressor effect relative to parent vasopressin — the modification eliminates the C-terminal glycinamide that contributes to peripheral V1a receptor engagement in vascular smooth muscle.
- 4Modulation of the HPA axis via central V1b receptor engagement in the pituitary, contributing to the neuroendocrine effects observed in the vasopressin-family research literature.
- 5Effects on ACTH release via the V1b receptor mechanism, producing indirect cortisol effects that may contribute to the memory-endpoint observations through stress-and-memory interactions.
- 6Reported effects on norepinephrine and serotonin systems in some preclinical work, providing an additional neurotransmitter-modulation angle for the observed cognitive effects.
- 7Preservation of memory-consolidation-relevant neural activity patterns in aged animal models, supporting the interpretation of a genuine central memory-modulation effect rather than a purely peripheral or endocrine effect.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Classical vasopressin-family memory-modulation research tool — the compound occupies a specific research-tool niche for probing vasopressin-family memory mechanisms.
- 2Separation of central memory effects from peripheral pressor effects — the mechanistic property that distinguishes DGAVP from parent vasopressin and makes chronic administration more feasible than parent-compound work.
- 3Reported memory improvements in age-related cognitive decline and alcohol amnestic state research from the classical evidence base.
- 4Historical significance in the cognitive-peptide research programme — the De Wied laboratory work is one of the foundational bodies of research that established peptides as memory-modulating research tools.
- 5Well-characterised acute-safety profile from decades of academic research use, providing a research-safety-framework advantage.
- 6Distinctive mechanism (vasopressin-family receptor engagement) providing a research-tool angle distinct from the modern cognitive-peptide clusters.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Intranasal / parenteral (research) | Microgram-to-milligram range in classical research protocols | Variable across research protocols | Short courses in most published research |
Note: Classical vasopressin-family research protocols are not directly comparable to modern cognitive-peptide dosing conventions; DGAVP-specific protocol standardisation is limited.
Section 6
Administration Routes
- Intranasal administration — the standard route in the classical vasopressin-family cognitive research literature, exploiting nose-to-brain delivery for CNS-targeted effects.
- Subcutaneous administration in animal research contexts.
- Intravenous administration in some classical human research protocols.
- Oral administration is not viable — the peptide is degraded by gastrointestinal proteases.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in the classical research at studied doses — the analogue's design specifically aimed at reducing the peripheral cardiovascular effects that limit parent-vasopressin research use.
- · Mild nasal irritation with intranasal administration — self-limiting.
- · Occasional mild transient effects on mood or arousal reported in the classical human research.
- · No dependence, tolerance, or withdrawal phenomena documented in the reported research base.
Rare / theoretical
- · Long-term safety data is limited — the compound was primarily used in short-course academic research rather than chronic clinical protocols.
- · Rare hypersensitivity reactions.
- · Residual peripheral vasopressin-family effects at higher doses — the pressor-effect reduction is substantial but not complete.
- · Theoretical interactions with vasopressin-active pharmaceuticals given the shared receptor system.
Contraindications
- · Not authorised for human use in the UK.
- · Pregnancy and lactation — no controlled data.
- · Concurrent use with vasopressin-family pharmaceuticals — pharmacodynamic redundancy.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Historical research peptide.
European Union
Not approved by the EMA.
Section 9
Clinical Studies Summary
DGAVP memory-modulation effects in the classical De Wied laboratory programme
The extended body of work from the De Wied laboratory characterising DGAVP's memory-modulation effects across animal and human research contexts, establishing the phenotypic separation of central memory effects from peripheral pressor effects and providing the foundational evidence base for the vasopressin-family cognitive research programme. The core historical reference for the compound.
DGAVP in age-related cognitive decline research
Classical human research applications of DGAVP in age-related cognitive decline populations reporting modest memory improvements over short-course intranasal administration, contributing to the historical vasopressin-cognitive-effect research angle without producing definitive replication-consistent evidence at Western-clinical-standard scale.
DGAVP mechanism-of-action characterisation
Molecular pharmacology characterisation of DGAVP's receptor pharmacology demonstrating selective central V1a and V1b receptor engagement with reduced peripheral V2 activity relative to parent vasopressin, providing the mechanistic scaffold for the observed phenotypic separation of central and peripheral effects.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing DGAVP for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain DGAVP from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.